Katharina Ronacher

Targeting GPR183 reduced lung fibrosis and inflammation in a preclinical model, supporting GPR183 as a promising new therapy.

This study shows that AVE0991, a Mas receptor agonist, reduces cytokines and viral titres in vitro but worsens disease in vivo in viral respiratory infections.

This study identifies trace-level cytokines in PASC patients linked to cardiovascular symptoms and shows their impact on cardiomyocyte function using nanotechnology detection.

This study identifies ancestry-specific eQTLs in TB-T2D patients using cis-eQTL mapping, revealing variants associated with gene expression that could guide therapeutic targets in African populations.